Literature DB >> 25676554

Overdiagnosis of high-grade dysplasia in Barrett's esophagus: a multicenter, international study.

Nikhil A Sangle1, Shari L Taylor2, Mary J Emond3, Michelle Depot4, Bergein F Overholt5, Mary P Bronner6.   

Abstract

Numerous histological mimics of high-grade dysplasia in Barrett's esophagus predispose to overdiagnosis and potential serious mismanagement, including unnecessary esophagectomy. This study investigates the prevalence and sources of this problem. Biopsies from 485 patients diagnosed with Barrett's high-grade dysplasia were screened for a multi-institutional, international Barrett's endoscopic ablation trial. Screening included review of the original diagnostic slides and an additional protocol endoscopy with an extensive biopsy sampling. Observer variability by the study pathologists was assessed through two blinded diagnostic rounds on 437 biopsies from 26 random study endoscopies. Study diagnostic reassessments revealed significantly lower rates of high-grade dysplasia. Only 248 patients (51%) were confirmed to have high-grade dysplasia. The remaining patients had inflamed gastric cardia without Barrett's (n=18; 7%), Barrett's without dysplasia (n=35; 15%), indefinite change (n=61; 26%), low-grade dysplasia (n=79; 33%), adenocarcinoma (n=43; 18%), and other (n=1; <1%), yielding an alarming total of 194 or 40% of patients who were overdiagnosed with Barrett's high-grade dysplasia. Study pathologists achieved a high-level agreement (90% three-way inter-observer agreement per biopsy, Kappa value 0.77) for high-grade dysplasia. Confounding factors promoting overdiagnosis included Barrett's inflammatory atypia (n=182), atypia limited to the basal metaplastic glands (n=147), imprecise criteria for low grade neoplasia (n=102), tangential sectioning artifact (n=59), and reactive gastric cardiac mucosa (n=38). A total of 194 patients (40%) were overdiagnosed with Barrett's high-grade dysplasia, as affirmed by the extensive screening process and high-level study pathologist agreement. The multiple diagnostic pitfalls uncovered should help raise pathologists' awareness of this problem and improve diagnostic accuracy.

Entities:  

Mesh:

Year:  2015        PMID: 25676554     DOI: 10.1038/modpathol.2015.2

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  18 in total

1.  The lower esophagus lined by columnar epithelium.

Authors:  N R BARRETT
Journal:  Surgery       Date:  1957-06       Impact factor: 3.982

2.  Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus.

Authors:  Kenneth K Wang; Richard E Sampliner
Journal:  Am J Gastroenterol       Date:  2008-03       Impact factor: 10.864

3.  Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett's esophagus biopsies.

Authors:  Erinn Downs-Kelly; Joel E Mendelin; Ana E Bennett; Elias Castilla; Walter H Henricks; Lynn Schoenfield; Marek Skacel; Lisa Yerian; Thomas W Rice; Lisa A Rybicki; Mary P Bronner; John R Goldblum
Journal:  Am J Gastroenterol       Date:  2008-07-30       Impact factor: 10.864

4.  Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial.

Authors:  Bergein F Overholt; Charles J Lightdale; Kenneth K Wang; Marcia I Canto; Steven Burdick; Roger C Haggitt; Mary P Bronner; Shari L Taylor; Michael G A Grace; Michelle Depot
Journal:  Gastrointest Endosc       Date:  2005-10       Impact factor: 9.427

Review 5.  Diagnosis and grading of dysplasia in Barrett's oesophagus.

Authors:  R D Odze
Journal:  J Clin Pathol       Date:  2006-10       Impact factor: 3.411

6.  Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation.

Authors:  E Montgomery; M P Bronner; J R Goldblum; J K Greenson; M M Haber; J Hart; L W Lamps; G Y Lauwers; A J Lazenby; D N Lewin; M E Robert; A Y Toledano; Y Shyr; K Washington
Journal:  Hum Pathol       Date:  2001-04       Impact factor: 3.466

7.  A study of indefinite for dysplasia in Barrett's oesophagus: reproducibility of diagnosis, clinical outcomes and predicting progression with AMACR (alpha-methylacyl-CoA-racemase).

Authors:  Sunil A Sonwalkar; Olorunda Rotimi; Nigel Scott; Eldo Verghese; Mike Dixon; Anthony T R A Axon; Simon M Everett
Journal:  Histopathology       Date:  2010-06       Impact factor: 5.087

8.  Grading of gastric foveolar-type dysplasia in Barrett's esophagus.

Authors:  Dipti Mahajan; Ana E Bennett; Xiaobo Liu; James Bena; Mary P Bronner
Journal:  Mod Pathol       Date:  2009-10-16       Impact factor: 7.842

9.  DNA ploidy abnormalities in basal and superficial regions of the crypts in Barrett's esophagus and associated neoplastic lesions.

Authors:  Xiaoqi Zhang; Qin Huang; Raj K Goyal; Robert D Odze
Journal:  Am J Surg Pathol       Date:  2008-09       Impact factor: 6.394

Review 10.  Barrett's esophagus, dysplasia, and adenocarcinoma.

Authors:  R C Haggitt
Journal:  Hum Pathol       Date:  1994-10       Impact factor: 3.466

View more
  12 in total

Review 1.  Development of Quality Indicators for Endoscopic Eradication Therapies in Barrett's Esophagus: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium.

Authors:  Sachin Wani; V Raman Muthusamy; Nicholas J Shaheen; Rena Yadlapati; Robert Wilson; Julian A Abrams; Jacques Bergman; Amitabh Chak; Kenneth Chang; Ananya Das; John Dumot; Steven A Edmundowicz; Glenn Eisen; Gary W Falk; M Brian Fennerty; Lauren Gerson; Gregory G Ginsberg; David Grande; Matt Hall; Ben Harnke; John Inadomi; Janusz Jankowski; Charles J Lightdale; Jitin Makker; Robert D Odze; Oliver Pech; Richard E Sampliner; Stuart Spechler; George Triadafilopoulos; Michael B Wallace; Kenneth Wang; Irving Waxman; Srinadh Komanduri
Journal:  Am J Gastroenterol       Date:  2017-06-01       Impact factor: 10.864

Review 2.  Quality Indicators in Endoscopic Ablation for Barrett's Esophagus.

Authors:  Samuel Han; Sachin Wani
Journal:  Curr Treat Options Gastroenterol       Date:  2017-06

Review 3.  [Pathology of early stage cancer of the gastrointestinal tract : Definition, principles and diagnosis].

Authors:  B Märkl; B Martin
Journal:  Chirurg       Date:  2018-05       Impact factor: 0.955

4.  p53 protein accumulation predicts malignant progression in Barrett's metaplasia: a prospective study of 275 patients.

Authors:  Mamoun Younes; Keith Brown; Gregory Y Lauwers; Gulchin Ergun; Frank Meriano; A Carl Schmulen; Alberto Barroso; Atilla Ertan
Journal:  Histopathology       Date:  2017-04-11       Impact factor: 5.087

Review 5.  Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines?

Authors:  Nicole E Rich; Amit G Singal
Journal:  Hepatology       Date:  2022-01-18       Impact factor: 17.425

6.  Increasing diagnostic accuracy to grade dysplasia in Barrett's esophagus using an immunohistochemical panel for CDX2, p120ctn, c-Myc and Jagged1.

Authors:  Dipti M Karamchandani; Heather L Lehman; Sara E Ohanessian; Julie Massé; Patricia A Welsh; Robert D Odze; John R Goldblum; Arthur S Berg; Douglas B Stairs
Journal:  Diagn Pathol       Date:  2016-02-29       Impact factor: 2.644

7.  Value of histomorphometric tumour thickness and smoothelin for conventional m-classification in early oesophageal adenocarcinoma.

Authors:  Katharina Endhardt; Bruno Märkl; Andreas Probst; Tina Schaller; Daniela Aust
Journal:  World J Gastrointest Oncol       Date:  2017-11-15

Review 8.  Barrett's esophagus: The pathomorphological and molecular genetic keystones of neoplastic progression.

Authors:  Ksenia S Maslyonkina; Alexandra K Konyukova; Darya Y Alexeeva; Mikhail Y Sinelnikov; Liudmila M Mikhaleva
Journal:  Cancer Med       Date:  2021-12-06       Impact factor: 4.452

Review 9.  Barrett's esophagus: Review of natural history and comparative efficacy of endoscopic and surgical therapies.

Authors:  Kevin Kyung Ho Choi; Santosh Sanagapalli
Journal:  World J Gastrointest Oncol       Date:  2022-03-15

10.  Persistent or recurrent Barrett's neoplasia after an endoscopic therapy session is associated with DNA content abnormality and can be detected by DNA flow cytometric analysis of paraffin-embedded tissue.

Authors:  Christopher J Bowman; Ruth Zhang; Dana Balitzer; Dongliang Wang; Peter S Rabinovitch; Bence P Kővári; Aras N Mattis; Sanjay Kakar; Gregory Y Lauwers; Won-Tak Choi
Journal:  Mod Pathol       Date:  2021-06-09       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.